Dr Daver on the Investigation of Uproleselan Plus Azacitidine and Venetoclax in AML
September 22nd 2023Naval G. Daver, MD, discusses the rationale for an ongoing phase 1 trial investigating uproleselan in combination with azacitidine and venetoclax in patients with treatment-naïve acute myeloid leukemia.
Read More
Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia
July 17th 2023Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.
Read More
An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia
June 26th 2023Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.
Read More
Dr. Daver Compares Toxicity Profiles of TKIs in CML
August 29th 2019Naval G. Daver, MD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses safety differences between the TKIs ponatinib, dasatinib (Sprycel) and nilotinib (Tasigna) in the treatment of patients with chronic myeloid leukemia.
Read More
Combination Checkpoint Therapy Gains Ground in AML and MDS
December 29th 2017Rational combinations of immune checkpoint inhibitors with other standard antileukemic agents may be needed to improve the response rates, the durability of response, and the overall survival in patients with AML/MDS.
Read More
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC
Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512